Learn More
Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response Multiple myeloma (MM) remains a predominantly incurable malignancy despite high-dose chemotherapy, autologous stem cell transplant and novel agents. 1 Proteasome inhibitors (PI) such as Bortezomib have increased the response rate(More)
  • 1